Medical Condition News

RSS

Smoking RA patients don't respond to anti-TNF drugs

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.

8 Jun 2012

Hypocaloric diet may help achieve minimal disease activity in psoriatic arthritis patients

According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.

8 Jun 2012

Special section of JNMD focuses on the impending release of revised DSM-5

The June issue of The Journal of Nervous and Mental Disease (JNMD) features a special section focused on the impending release of the revised Diagnostic and Statistical Manual of Mental Disorders (DSM-5), an update to psychiatric diagnosis standards.

8 Jun 2012

Large-scale randomized treatment study on adrenocortical cancer

Adrenocortical cancer is an uncommon form of cancer that is often fatal. For the first time, a large-scale randomized treatment study has now been carried out. The study is being published in the prestigious New England Journal of Medicine and constitutes an important and long-awaited platform for continued research.

8 Jun 2012

Concussion victims have unique spatial patterns of brain abnormalities that change over time

Patients vary widely in their response to concussion, but scientists haven't understood why. Now, using a new technique for analyzing data from brain imaging studies, researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that concussion victims have unique spatial patterns of brain abnormalities that change over time

8 Jun 2012

NKI-AVL, Elekta partner to advance cancer research

Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital have signed a strategic alliance to advance cancer research.

From Elekta 8 Jun 2012

LBDA launches nationwide October awareness movement

Today the Lewy Body Dementia Association (LBDA) launched its nationwide October awareness movement, "A Month To Remember." LBDA invites volunteers to join the movement by "Standing Strong with LBDA" to build awareness for Lewy body dementia in their communities.

8 Jun 2012

SVS, Elsevier to launch Journal of Vascular Surgery

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the Society for Vascular Surgery announce the launch of a new quarterly journal, Journal of Vascular Surgery: Venous and Lymphatic Disorders. The inaugural issue will appear in January, 2013.

8 Jun 2012

DiaGenic initiates [18F] Flutemetamol PET imaging clinical study in MCI

DiaGenic ASA today announced that the first patient with MCI (Mild Cognitive Impairment) was examined with [18F] Flutemetamol PET imaging at University of Lund Sweden in the DiaGenic and GE Healthcare Research Collaboration announced March 27th 2012.

8 Jun 2012

Accuray announces outcome data from CyberKnife Prostate SBRT study

Accuray Incorporated, the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife Prostate SBRT was presented at the American Urological Association Meeting (AUA) 2012 held in Atlanta, Ga.

8 Jun 2012

Second-hand cigarette smoke linked with moderate to severe urinary disorders in children

According to the Environmental Protection Agency, parents are responsible for 90 percent of children's exposure to environmental (second-hand) tobacco smoke. Children with mothers who smoke are at even higher-risk for developing health disorders.

8 Jun 2012

Erivedge drug shows promise against advanced basal cell carcinoma

It's the most common form of skin cancer, but in its advanced stages, basal cell carcinoma has the potential to become disfiguring and life threatening. An international phase 2 study headed by Mayo Clinic led to the recent Food and Drug Administration approval of the first drug of its kind to help advanced basal cell carcinoma patients who have few treatment options.

8 Jun 2012

Researchers shed light on key biological events that may lead to new disease treatments

In exploring how proteins interact with crucial DNA sequences to regulate gene activity, researchers have shed light on key biological events that may eventually be manipulated to provide new disease treatments.

8 Jun 2012

Lung changes in association with ACPA status are a primary manifestation of RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA).

8 Jun 2012

Data from abatacept versus adalimumab Phase IIIb comparison study on RA

Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20.

8 Jun 2012

Study packs powerful one-two punch in the fight against heart failure

A new study in the journal Circulation packs a powerful one-two punch in the fight against heart failure. The leading blow: Identification of a unique alliance of proteins that plays a major role in the development of the disease. The second but equally powerful hit: Drugs that interfere with this axis already exist.

8 Jun 2012

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

8 Jun 2012

Patients over 45 years with history of early menopause 50% less likely to develop severe RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA).

8 Jun 2012

Cardinal Health to launch new technology enhancements at SNM annual meeting

At the Society of Nuclear Medicine's (SNM) 59th Annual Meeting in Miami Beach, Fla., June 9-12, Cardinal Health will introduce new technology enhancements that make it possible for hospital nuclear medicine departments and imaging centers to seamlessly improve data integration and the overall efficiency of their operations.

8 Jun 2012

Experts debate whether spinal manipulation for neck pain should be abandoned

The effectiveness of spinal manipulation divides medical opinion. On bmj.com today, experts debate whether spinal manipulation for neck pain should be abandoned.

8 Jun 2012